SuperworthPrecigen EPS PGEN
Diluted earnings per share by quarter and over the last twelve months, from 2012.
- Last 12 months, to Jun 30, 2026
- −$1.10
- Latest quarter, Q2 FY26
- $0.05
- Fiscal year 2025
- −$1.40
Precigen's earnings per share was −$1.10 over the twelve months to Jun 30, 2026.
In its latest quarter, Q2 FY26, it was $0.05.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$1.40 | n/a |
| FY2024 | −$0.49 | n/a |
| FY2023 | −$0.39 | −379% |
| FY2022 | $0.14 | n/a |
| FY2021 | −$0.47 | n/a |
| FY2020 | −$1.02 | n/a |
| FY2019 | −$2.09 | n/a |
| FY2018 | −$3.90 | n/a |
| FY2017 | −$0.98 | n/a |
| FY2016 | −$1.58 | n/a |
| FY2015 | −$0.74 | n/a |
| FY2014 | −$0.83 | n/a |
| FY2013 | −$9.97 | n/a |
| FY2012 | −$18.72 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.05 | n/a | −$1.10 | |
| Q1 FY26 | −$0.02 | n/a | −$1.24 | |
| Q4 FY25 | −$0.07 | n/a | −$1.40 | |
| Q3 FY25 | −$1.06 | n/a | −$1.40 | |
| Q2 FY25 | −$0.09 | n/a | −$0.43 | |
| Q1 FY25 | −$0.18 | n/a | −$0.57 | |
| Q4 FY24 | −$0.07 | n/a | −$0.49 | |
| Q3 FY24 | −$0.09 | n/a | −$0.55 | |
| Q2 FY24 | −$0.23 | n/a | −$0.54 | |
| Q1 FY24 | −$0.10 | n/a | −$0.39 | |
| Q4 FY23 | −$0.13 | n/a | −$0.39 | |
| Q3 FY23 | −$0.08 | −118% | −$0.37 |
Against its peers
Companies in Drug Manufacturers - General nearest Precigen's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| PGENPrecigen | −$1.10 | |
| PBHPrestige Consumer Healthcare | $3.57 | −16% a year |
| HRMYHarmony Biosciences | $3.09 | −0% a year |
| NRIXNurix Therapeutics | $2.31 | |
| ANIPANI Pharmaceuticals | $4.70 | |
| PAHCPhibro Animal Health | $2.44 | +107% a year |
| ANABAnaptysbio | $4.57 | |
| PCRXPacira BioSciences | $0.35 | |
| OGNOrganon | $0.77 | −71% a year |
| LQDALiquidia | $1.39 | |
| ARQTArcutis Biotherapeutics | $0.22 | |
| Peer median | $2.38 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Precigen
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.